Background. P-selectin (PS) is a marker of platelet activation measured on the platelet surface as platelet PS (pPS) or in serum as soluble PS (sPS). Controversy remains over the exact relationship between sPS, pPS, and other markers such as spontaneous platelet aggregation (SPA). Objective. To investigate correlations between pPS, sPS, and SPA in patients with peripheral arterial disease. Methods. SPA, pPS, and sPS levels were measured in venous blood sampled from patients following intermittent claudication (n = 18) or an acute stroke (n = 18). Results. SPA and sPS correlated significantly in the claudicants (Pearson correlation coefficient, r = 0.661; P = .0020) and stroke patients (r = 0.514; P = .020). No significant correlation was identified between pPS and SPA, or sPS and pPS. Conclusions. The 2 methods of assessing PS are not comparable. Although pPS is accepted as a platelet activation marker, sPS may be a better indicator of aggregation represented by SPA.
Tsiara S., Elisaf M., Jagroop IA, Mikhailidis DPPlatelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003;9: 177-190.
2.
Robless P., Mikhailidis DP, Stansby G.Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001;88:787-800.
3.
Shattil SJ, Cunningham M., Hoxie JADetection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood Coagul Fibrinolysis . 1987;70:307-315.
4.
Schmitz G., Herr AS, Rothe G.T-lymphocytes and monocytes in atherogenesis. Herz. 1998;23:168-177.
5.
Robless P., Okonko D., Lintott P., Mansfield A., Mikhailidis D., Stansby G.Increased platelet aggregation and activation in peripheral arterial disease . Eur J Vasc Endovasc Surg. 2003;25:16-22.
6.
Barradas MA, Stansby G., Hamilton G., Mikhailidis DPEffect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease. In Vivo. 1993;7:543-548.
7.
McCabe DJ , Harrison P., Mackie IJ, et al. Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. Br J Haematol . 2004;125:777-787.
8.
Fagerstam JP , Whiss PA, Strom M., Andersson RGExpression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res. 2000;49:466-472.
9.
Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, O'Connor CM, Serebruany VLRole of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. Am Heart J.2000;139:320-328.
10.
Kamath S., Blann AD, Caine GJ, Gurney D., Chin BS, Lip GYPlatelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke. 2002 ;33:1237-1242.
11.
O'Conner CM , Gurbel PA, Serebruany VLUsefulness of soluble and surface bound P-selectin activity in patients with congestive heart failure. Am J Cardiol.1999;83:1345-1349.
12.
Makin AJ, Chung NA, Silverman SH, Lip GYAlterations of thrombogenesis, endothelial damage and oxidative stress with reperfusion during femoral artery bypass surgery for peripheral vascular disease . Pathophysiol Haemost Thromb. 2002;32:158-164.
13.
Blann AD, Dobrotova M., Kubisz P., McCollum CNVon Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626-630.
14.
Parker C. 3rd, Vita JA, Freedman JESoluble adhesion molecules and unstable coronary artery disease. Atherosclerosis. 2001;156:417-424.
15.
Makin AJ, Chung NA, Silverman SH, Moss MS, Lip GYIndices of thrombogenesis, endothelial damage and platelet function following percutaneous peripheral artery angiography and angioplasty for peripheral vascular disease. Pathophysiol Haemost Thromb. 2003;33: 102-108.
16.
Warzok F., Steiner M., Blann AD, Weber F., Urbaszek W., Schuff-Werner P.Immediate and late effects of coronary angiography on soluble endothelial cell markers and P-selectin in patients with and without coronary artery disease . Blood Coagul Fibrinolysis. 1999;10:381-387.
17.
Ridker PM, Buring JE, Rifai N.Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491-495.
18.
Barbaux SC, Blankenberg S., Rupprecht HJ, et al. Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:1668-1673.
19.
Tsakiris DA, Tschopl M., Jager K., Haefeli WE, Wolf F., Marbet GACirculating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis. 1999;142:193-200.
20.
Kirkpatrick UJ, Mossa M., Blann AD, McCollum CNRepeated exercise induces release of soluble P-selectin in patients with intermittent claudication. Thromb Haemost. 1997;78:1338-1342.
21.
Lindmark E. , Wallentin L., Siegbahn A.Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease. Thromb Res . 2001;103: 249-259.
22.
Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998;31:352-358.
23.
Knight CJ, Panesar M., Wright C., et al. Altered platelet function detected by flow cytometry. Effects of coronary artery disease and age. Arterioscler Thromb Vasc Biol. 1997;17:2044-2053.
24.
Cha JK, Jo WS, Shin HC, Bae HR, Ho JM, Kim JWIncreased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke. Platelets. 2004;15:3-7.
25.
Marquardt L. , Ruf A., Mansmann U., et al. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33:2570-2574.
26.
Cassar K., Bachoo P., Ford I., Greaves M., Brittenden J.Platelet activation is increased in peripheral arterial disease. J Vasc Surg. 2003;38:99-103.
27.
Cherian P., Hankey GJ, Eikelboom JW, et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke. 2003 ;34:2132-2137.
28.
Tan KT, Tayebjee MH, Lynd C., Blann AD, Lip GYPlatelet microparticles and soluble p-selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med. 2005;37:61-66.
29.
Trip MD, Cats VM, van Capelle FJ, Vreeken J.Platelet hyperreactivity and prognosis in survivors of myocardial infarction . N Engl J Med. 1990; 322:1549-1554.
30.
Vasilieva EJ , Orlov VN, Barkagan ZSShape and spreading of platelets from the blood of patients with acute myocardial infarction. Thromb Haemost. 1984;52:201-204.
31.
Ward AS, Porter N., Preston FE, Morris-Jones W.Platelet aggregation in patients with peripheral vascular disease. Atherosclerosis. 1978;29:63-68.
32.
Mettinger KL , Nyman D., Kjellin KG, Siden A., Soderstrom CEFactor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease: a study of stroke before 55. J Neurol Sci. 1979;41:31-38.
33.
Jackson SP, Salem HHPlatelet aggregating activity in the plasma of patients with established thrombosis . Aust N Z J Med. 1989;19:126-131.
34.
Holmes MB, Sobel BE, Howard DB, Schneider DJDifferences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIa expression and their clinical implications. Thromb Res. 1999;95:75-82.
35.
Setiadi H., Disdier M., Green SA, Canfield WM, McEver RPResidues throughout the cytoplasmic domain affect the internalization efficiency of P-selectin. J Biol Chem. 1995;270:818-826.
36.
Semenov AV, Romanov YA, Loktionova SA, et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry. 1999;64:1326-1335.
37.
Jilma B., Eichler HG, Becherer A., et al. Kinetics of circulating selectin levels during bone marrow aplasia . Eur J Haematol. 1998;61:36-41.
38.
Vianelli N. , Catani L., Gugliotta L., et al. Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura. Haematologica . 1996;81:3-7.
39.
Katayama M. , Handa M., Araki Y., et al. Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol. 1993;84:702-710.
Fijnheer R. , Frijns CJ, Korteweg J., et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost. 1997;77:1081-1085.
42.
Blann AD, Lip GY, Beevers DG, McCollum CNSoluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost. 1997 ;77:1077-1080.
43.
Verhaar MC, Beutler JJ, Gaillard CA, Koomans HA, Fijnheer R., Rabelink TJProgressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens. 1998 ;16:45-50.
